GTBP GT Biopharma, Inc.

NASDAQ
$6.89

GT Biopharma, Inc. (GTBP) is expected to report earnings on November 16, 2026, before the market open. The consensus earnings estimate is a loss of $2.50 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -6.6% since its last earnings release on August 14, 2026.

GT Biopharma Missed Consensus Estimates
Friday, August 14, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 16
Monday · 8:00 AM ET
Earnings Whisper
-
vs ($2.50)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $8.47

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About GT Biopharma, Inc.

GT Biopharma Inc. is an immuno-oncology company. It discovers, develops and commercializes drugs of therapeutic molecules for the treatment of cancer, myeloma, osteolytic lesions and other unmet medical needs. GT Biopharma Inc., formerly known as OXIS International Inc., is based in Tampa, Florida.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.